BCBS North Carolina coverage for Zepbound (Osa)

Employer / Commercial Insurance

Depends on your plan's benefit

Patient must have anti-obesity medication coverage benefits (criterion 7 of initial criteria; criterion 4 of continuation criteria)

What you need to qualify

Age 18 and older
BMI of 30 or higher
6 months of a documented diet and exercise program
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA in adults with obesity

All of:

Patient is 18 years of age or older
Diagnosis of moderate to severe obstructive sleep apnea
BMI >= 30 kg/m2
Polysomnography (PSG) or home sleep apnea test performed
Apnea hypopnea index (AHI) >= 15 at baseline
Requested medication will NOT be used concurrently with another GLP-1 receptor agonist
Requested medication will NOT be used concurrently with another weight loss medication
Provider has addressed requirement for lifestyle modifications
Patient has anti-obesity medication coverage benefits

Plus any one of:

Patient was unable to achieve acceptable weight loss (1 lb/week) through lifestyle modifications over 6 months
Patient has a weight-related comorbidity (e.g., OSA) that warrants immediate medication intervention

Documentation to bring

Documentation of moderate to severe obstructive sleep apnea diagnosis
Baseline BMI >= 30 kg/m2
Polysomnography (PSG) or home sleep apnea test results showing AHI >= 15 at baseline
Documentation that provider addressed lifestyle modification requirement
Documentation of 6-month lifestyle modification attempt with failure to achieve 1 lb/week weight loss, OR documentation of OSA as weight-related comorbidity warranting immediate medication intervention
Documentation that patient is not concurrently using another GLP-1 receptor agonist
Documentation that patient is not concurrently using another weight loss medication
Confirmation of anti-obesity medication coverage benefits

Quantity limits

2.5 mg/0.5 mL — 4 pens per 28 days

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for Patient with OSA must demonstrate a positive clinical response while using the medication. No weight loss percentage threshold required for continuation of OSA indication.

Not covered when

Concurrent use of another GLP-1 receptor agonist
Concurrent use of another weight loss medication

Policy note: OSA indication for Zepbound added January 2025, criteria updated April 2025. Policy requires AHI >= 15 (moderate OSA threshold) confirmed by PSG or home sleep apnea test. No PAP therapy trial requirement stated. The OSA pathway requires BMI >= 30 (not BMI >= 27 with comorbidity). Continuation for OSA requires positive clinical response rather than a specific weight loss percentage. The lifestyle modification criteria (items 3-6) from the broader initial criteria section apply to all drugs in the Foundayo/Saxenda/Wegovy/Zepbound group including OSA indication.

Policy effective July 1, 2026 · verified July 16, 2026 · source: Pa policy